These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 22018894)

  • 1. Experience with extracorporeal elimination therapy in myasthenia gravis.
    Blaha M; Pitha J; Blaha V; Lanska M; Maly J; Filip S; Brndiar M; Langrova H
    Transfus Apher Sci; 2011 Dec; 45(3):251-6. PubMed ID: 22018894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.
    Köhler W; Bucka C; Klingel R
    J Clin Apher; 2011 Dec; 26(6):347-55. PubMed ID: 22095647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-term treatment of refractory myasthenia gravis with immunoadsorption].
    Wagner S; Janzen RW; Mohs C; Pohlmann S; Klingel R; Grützmacher PW
    Dtsch Med Wochenschr; 2008 Nov; 133(46):2377-82. PubMed ID: 18988129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma exchange in elderly patients.
    Basic-Jukic N; Brunetta B; Kes P
    Ther Apher Dial; 2010 Apr; 14(2):161-5. PubMed ID: 20438537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Plasmapheresis in patients with myasthenia gravis].
    Konishi T
    Nihon Rinsho; 2008 Jun; 66(6):1165-71. PubMed ID: 18540364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis.
    Jensen P; Bril V
    J Clin Neuromuscul Dis; 2008 Mar; 9(3):352-5. PubMed ID: 18344718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of severe forms of myasthenia gravis.
    Iani C; Caramia M; Morosetti M; Loberti M; Palmieri MG; Meloni C; Gallucci MT; Casciani CU; Bernardi G
    Funct Neurol; 1998; 13(3):231-7. PubMed ID: 9800150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis non-responsive to immunosuppressive agents: an eight year follow-up.
    Triantafyllou NI; Grapsa EI; Kararizou E; Psimenou E; Lagguranis A; Dimopoulos A
    Ther Apher Dial; 2009 Jun; 13(3):174-8. PubMed ID: 19527462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Favorable results of plasmapheresis in severe myasthenia gravis].
    Blom RJ; Kuks JB; Westerterp-Maas A; Oosterhuis HJ
    Ned Tijdschr Geneeskd; 1997 Feb; 141(8):381-4. PubMed ID: 9157298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fundamental studies with respect to plasma exchange by using continuous-flow centrifuge system and the clinical trial in patients with myasthenia gravis].
    Suga M; Akahonai Y; Tsujisaki M; Mori M; Yoshizaki H; Matsumoto H; Yachi A
    Hokkaido Igaku Zasshi; 1982 Nov; 57(6):734-40. PubMed ID: 7183499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group.
    Gajdos P; Chevret S; Clair B; Tranchant C; Chastang C
    Ann Neurol; 1997 Jun; 41(6):789-96. PubMed ID: 9189040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma exchange therapy for severe penicillamine-induced myasthenia gravis.
    Lang AE; Humphrey JG; Gordn DA
    J Rheumatol; 1981; 8(2):303-7. PubMed ID: 7230162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Plasmapheresis-pulse therapy in myasthenia gravis].
    Jyoichi T; Noda Y; Mizuguchi M; Shimojo S; Miyahara T
    Rinsho Shinkeigaku; 1988 Jan; 28(1):43-50. PubMed ID: 3383512
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of plasma exchange therapy in patients with myasthenia gravis.
    Ebadi H; Barth D; Bril V
    Muscle Nerve; 2013 Apr; 47(4):510-4. PubMed ID: 23322564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunoadsorption therapy for myasthenia gravis: study on the adsorption capacity of an immunoadsorption column].
    Yeh JH; Chiu HC
    J Microbiol Immunol Infect; 1999 Jun; 32(2):121-5. PubMed ID: 11565565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoadsorption in Guillain-Barré syndrome and myasthenia gravis.
    Haupt WF; Rosenow F; van der Ven C; Birkmann C
    Ther Apher; 2000 Jun; 4(3):195-7. PubMed ID: 10910018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In-vitro and in-vivo studies on the selective immunoadsorption treatment of neurological diseases].
    Heininger K
    Schriftenr Neurol; 1993; 33():1-91. PubMed ID: 8327864
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term treatment of myasthenia gravis with immunoadsorption.
    Haas M; Mayr N; Zeitlhofer J; Goldammer A; Derfler K
    J Clin Apher; 2002; 17(2):84-7. PubMed ID: 12210711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elimination of IgG subclasses of anti-acetylcholine receptor antibodies in myasthenic plasma by immunoadsorption to protein A.
    Szpirt W; Somnier F; Nielsen FC; Rødgaard A
    Life Support Syst; 1985; 3 Suppl 1():351-5. PubMed ID: 3916613
    [No Abstract]   [Full Text] [Related]  

  • 20. Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis.
    Allen JA; Scala S; Jones HR
    Muscle Nerve; 2010 Mar; 41(3):379-84. PubMed ID: 19918767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.